$720 Million is the total value of BROADWOOD CAPITAL INC's 7 reported holdings in Q3 2019. The portfolio turnover from Q2 2019 to Q3 2019 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| LCTX | New | LINEAGE CELL THERAPEUTICS IN | $33,325,000 | – | 34,005,379 | +100.0% | 4.63% | – |
| OCX | Buy | ONCOCYTE CORPORATION | $23,306,000 | +15.6% | 11,098,267 | +37.0% | 3.24% | +28.3% |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| STAAR SURGICAL CO | 42 | Q3 2023 | 59.1% |
| MONSTER BEVERAGE CORP NEW | 34 | Q3 2023 | 49.7% |
| ISHARES TR | 33 | Q3 2023 | 14.8% |
| ONCOCYTE CORPORATION | 31 | Q2 2023 | 4.6% |
| BIOTIME INC | 25 | Q2 2019 | 17.8% |
| AXON ENTERPRISE INC | 24 | Q3 2023 | 13.4% |
| AGEX THERAPEUTICS INC | 20 | Q3 2023 | 1.5% |
| LINEAGE CELL THERAPEUTICS INC | 17 | Q3 2023 | 5.1% |
| ASTERIAS BIOTHERAPEUTICS INC | 16 | Q4 2018 | 2.9% |
| CYNOSURE INC | 15 | Q4 2016 | 10.4% |
View BROADWOOD CAPITAL INC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-04-15 |
| 13F-HR | 2024-02-14 |
| 4 | 2024-02-08 |
| 4 | 2024-01-10 |
| 4 | 2024-01-05 |
| 4 | 2023-11-30 |
| 13F-HR | 2023-11-14 |
| 4 | 2023-11-14 |
| 4 | 2023-11-09 |
| 4 | 2023-11-06 |
View BROADWOOD CAPITAL INC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.